Resiquimod - Galderma
Alternative Names: CD 11301.; R 848; S 28463; VML 600Latest Information Update: 29 Nov 2022
Price :
$50 *
At a glance
- Originator 3M Pharmaceuticals
- Developer Galderma; Spirig Pharma
- Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
- Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cutaneous T-cell lymphoma
- Discontinued Actinic keratosis; Basal cell cancer; Hepatitis C; Herpes simplex virus infections; Immunological disorders
Most Recent Events
- 29 Nov 2022 No development reported - Phase-II for Cutaneous T-cell lymphoma in France (Topical)
- 29 Nov 2022 No development reported - Phase-II for Cutaneous T-cell lymphoma in Germany (Topical)
- 29 Nov 2022 No development reported - Phase-II for Cutaneous T-cell lymphoma in USA (Topical)